Advance Lifes. (521048)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades below book value: price ₹41.99 vs book value ₹44.82, P/B 0.94
• Small market cap of ₹26 Cr leaves room for potential asset monetisation or control action
• Sharp rise from 52-week low of ₹20.05 suggests some investor interest or re-rating
• Low entry price relative to stated net worth offers a possible margin of safety if assets are genuine

Concerns

• Latest quarter sales and net profit are both ₹0 Cr, with 0% sales/profit growth
• ROE of 2.51% and ROCE of 4.43% indicate poor returns on equity and capital
• Piotroski F-Score of 3/9 points to weak fundamentals and financial health
• No dividend, no promoter holding data, and no debt-equity disclosure create opacity

AI Analysis

At ₹41.99, Advance Lifes. looks like the kind of cigar butt Graham might have examined. The market caps the company at just ₹26 Cr, while book value stands at ₹44.82 per share, so the stock trades at 0.94 times book. That appears to offer a margin of safety. But a low P/B only matters if the assets are real and can generate returns. Here, ROE is just 2.51% and ROCE is 4.43% – far below what I'd expect from a good business. The latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr, and historical sales and profit growth are also 0.00%. This is not a growing franchise; it is a stagnant or barely operating entity. The P/E of 22.25 on such weak earnings is not cheap; it only reflects a very small earnings base. The Piotroski F-Score of 3/9 reinforces my concern about weak financial health. There is no dividend, no promoter holding data, and no debt-equity ratio disclosed, leaving too many unknowns. In the textile industry, with commodity products and no visible moat, low returns are common. So I would classify this as an asset play, not a great business. The share price is below stated book value, but the ultimate worth depends on whether those assets are truly valuable – or just stale inventory and old machinery. I would not buy on hope alone. I need evidence of operational improvement, clarity on liabilities, and honest capital allocation before trusting this apparent discount.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer